Task: Answer Verification
Input (English): Question: Does addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study?
Answer: The addition of AEG35156 to reinduction chemotherapy was well tolerated but did not improve rates of remission. Therefore alternative therapeutic strategies should be explored in patients with AML refractory to induction chemotherapy.
Output (English): no